FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
CAMBRIDGE, Mass., March 02, 2016 -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the Cowen & Company 36th Annual Health Care Conference in Boston. Chief Executive Officer Mary Szela is scheduled to present on Wednesday, March 9, 2016 at 11:20 a.m. ET.
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Aegerion’s website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations 857-242-5024
